MK-1167: a business-reason halt for an alpha7 nicotinic modulator in Alzheimer's

What was tried

Merck ran a Phase 2 randomized, quadruple-masked, placebo-controlled study (NCT06721156) of MK-1167, an oral positive allosteric modulator of the alpha7 nicotinic acetylcholine receptor, given as adjunctive therapy on top of acetylcholinesterase inhibitors in mild-to-moderate Alzheimer's disease dementia. The trial enrolled 369 participants across four arms, testing 3 mg, 1 mg, and 0.3 mg once daily against placebo for roughly 24 weeks. The primary efficacy endpoint was the change from baseline in the 11-item Alzheimer's Disease Assessment Scale cognitive subscale (ADAS-Cog11) at week 24, alongside standard safety endpoints. The study started in December 2024 and recorded a primary completion date of 5 June 2026 before it was terminated. MK-1167 originated at Neuphoria Therapeutics, formerly Bionomics, and Merck paid a 15 million dollar milestone when the Phase 2 began. The reason logged on the registry was terse: "Termination Notes: Business reason."

The biological hypothesis

The alpha7 nicotinic acetylcholine receptor is a fast, calcium-permeable cation channel enriched in the hippocampus and cortex, regions central to memory. Enhancing signaling through it improves attention and cognition in preclinical models, which made it a decades-long target for cognitive disorders. A positive allosteric modulator amplifies the receptor's response to endogenous acetylcholine rather than opening the channel directly, a design intended to preserve physiological firing patterns and to avoid the rapid desensitization that blunted earlier direct agonists. Adding a modulator on top of acetylcholinesterase inhibitors was meant to push more signal through an already cholinergic-augmented system. The appeal of a modulator over a direct agonist was precisely this preservation of endogenous timing, because agonists tend to drive the receptor into a non-conducting, desensitized state that erodes any cognitive benefit over days of repeated dosing. Open Targets gives CHRNA7 a direct association score of 0.437 for Alzheimer's disease, but that score is weighted toward literature rather than human genetics, and alpha7 modulation is a symptomatic cholinergic mechanism rather than a disease-modifying one.

What actually happened

No efficacy results were posted to the registry. What is on the public record is that Merck halted an adequately sized, placebo-controlled Phase 2 and attributed the decision to a business reason. Independent reporting fills in the gap. Trade coverage described the study as stopped after an interim analysis in which the candidate did not meet the efficacy requirements needed to justify continued development, and specified that the decision was not driven by safety. A business reason recorded on the registry therefore sits on top of an interim efficacy signal. The distinction matters, because a strategic label can hide a mechanistic readout that other developers need to see. The termination also landed during a difficult period for the originator, compounding the setback for the alpha7 approach.

Failure mechanism, best guess

The alpha7 nicotinic receptor is a graveyard for cognition programs. Encenicline (EVP-6124), a selective partial agonist, produced encouraging Phase 2 cognitive signals in Alzheimer's disease, then had its Phase 3 program placed on clinical hold in 2015 for rare but serious gastrointestinal events and later missed cognition endpoints in two Phase 3 schizophrenia trials. AbbVie's ABT-126 was discontinued in Alzheimer's after Phase 2, and GTS-21 never produced durable benefit. The recurring pattern is strong receptor pharmacology without a durable, clinically meaningful cognition gain. Two mechanistic reasons fit. Alpha7 signaling is not the rate-limiting driver of Alzheimer's decline, so augmenting it lifts a symptomatic dial rather than changing disease trajectory, and receptor desensitization limits sustained effect even with a modulator design. Layering MK-1167 on top of acetylcholinesterase inhibitors left little cholinergic headroom to capture. The broader cholinergic hypothesis of Alzheimer's disease has delivered modest symptomatic relief but no arrest of decline, and a modulator that leans on the same pathway inherits that ceiling. The most parsimonious reading of an interim futility stop is that MK-1167 repeated the class outcome rather than breaking from it.

How to prevent this next time

Two quantitative tools would have set expectations before the interim. First, Bayesian predictive probability of success with a pre-specified futility boundary, written as

PP(success)=∫θ​P(final success∣θ,interim data)⋅π(θ∣interim data)dθ

turns the interim look into a transparent rule rather than a quiet business decision, and it lets the sponsor commit in advance to the ADAS-Cog11 effect size worth continuing for. Second, historical base-rate adjustment anchors the prior to reality: across 2002 to 2012, Alzheimer's programs failed at a rate of 99.6 percent, with 92 percent of Phase 2 programs and 98 percent of Phase 3 programs not advancing (Cummings, Morstorf and Zhong, 2014). A prior built on that record, combined with the specific alpha7 failure history, should have demanded a confirmatory target-engagement readout, such as receptor-occupancy positron emission tomography establishing that the tested doses achieved central alpha7 modulation, before a large efficacy bet. The single highest leverage change would have been requiring a pre-registered, occupancy-anchored interim futility rule that separated a genuine mechanistic miss from a dosing or exposure shortfall, so the readout could inform the field instead of disappearing behind a business label.

What this means for similar programs

Symptomatic cholinergic mechanisms added on top of acetylcholinesterase inhibitors face a steep bar in Alzheimer's disease, and the alpha7 nicotinic receptor in particular has now absorbed repeated failures across agonists and modulators. Future alpha7 programs should carry an explicit, occupancy-linked efficacy hypothesis and a public interim rule, because the value of a negative Phase 2 to the field collapses when the outcome is filed as a business reason.

Open questions

Did MK-1167 achieve adequate central alpha7 receptor occupancy at the doses tested, and was that measured? What did the interim ADAS-Cog11 trajectory actually show across the three doses? Would an earlier-stage or monotherapy population have behaved differently? And is alpha7 modulation viable for any cognitive indication after this many negative reads?

Sources

1. • ClinicalTrials.gov, NCT06721156, study record (accessed 2026-07-07): https://clinicaltrials.gov/study/NCT06721156 . Source for 369 participants, the four arms and doses, ADAS-Cog11 at week 24, adjunctive design, start date, primary completion 5 June 2026, and the recorded termination reason. - Fierce Biotech. Merck halts phase 2 Alzheimer's trial after Neuphoria small molecule underwhelms, 2026: https://www.fiercebiotech.com/biotech/merck-halts-ph-2-alzheimers-trial-after-neuphoria-small-molecule-underwhelms - Clinical Trial Vanguard. Neuphoria Therapeutics gets 15 million dollar milestone payment from Merck: https://www.clinicaltrialvanguard.com/news/neuphoria-therapeutics-gets-15m-milestone-payment-from-merck/ - Cummings J. L., Morstorf T., Zhong K. Alzheimer's disease drug-development pipeline: few candidates, frequent failures. Alzheimer's Research and Therapy, 2014.- Deardorff W. J. and Grossberg G. T. Safety and clinical effects of EVP-6124 in subjects with Alzheimer's disease. Expert Review of Neurotherapeutics, 2015.- Keefe R. S. E. et al. Randomized, double-blind, placebo-controlled study of encenicline, an alpha7 nicotinic acetylcholine receptor agonist. Neuropsychopharmacology, 2015.- Terry A. V. and Callahan P. M. Role of the alpha7 nicotinic acetylcholine receptor in Alzheimer's disease drug development. Drug Development Research, 2023.- Open Targets Platform, target CHRNA7 (ENSG00000175344), direct disease association scores (accessed 2026-07-07): https://platform.opentargets.org/target/ENSG00000175344.